Varas-Lorenzo C, Riera-Guardia N, Calingaert B, Margulis A, Pladevall M, Miguel G, Romio S, Sturkenboom M, Perez-Gutthann S. Cardiovascular risk with glitazones and metformin: results from a systematic review of observational studies. Poster presented at the 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management; August 2013. [abstract] Pharmacoepidemiol Drug Saf. 2013 Oct 7; 22(S1):68.
Riera Guardia N, Margulis AV, Pladevall-Vila M, Varas-Lorenzo C, Perez-Gutthann S. Methods issues in observational studies of the cardiovascular risk associated with glucose-lowering medications: results of a systematic review and evaluation. Poster presented at the 29th International Conference on Pharmacoepidemiology & Therapeutic Risk Management; October 7, 2013. [abstract] Pharmacoepidemiol Drug Saf. 22(Suppl 1):S80-81.
Pladevall M, Zografos L, Tatt I, Napalkov P, Andrews E, Perez-Gutthann S. Feasibility evaluation for a rituximab utilization study to be conducted in infusion centers. Poster presented at the 29th International Conference on Pharmacoepidemiology; August 2013.
Margulis AV, Pladevall-Vila M, Riera Guardia N, Varas-Lorenzo C, Hazell L, Perez-Gutthann S. Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastele-Ottawa Scale and the RTI Item Bank. Poster presented at the 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management; August 2013.
Pladevall-Vila M, Varas-Lorenzo C, Margulis AV, Riera Guardia N, Calingaert B, Romio S. Rosiglitazone vs. pioglitazone and acute myocardial infarction: systematic review and meta-analysis of observational studies. Presented at the 29th International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2013.
Hayek S, Canepa Escaro FC, Sattar A, Gamalski S, Wells KE, Divine G, Ahmedani BK, Lanfear DE, Pladevall M, Williams LK. Effect of ezetimibe on major atherosclerotic disease events and all-cause mortality. Am J Cardiol. 2013 Feb 1;111(4):532-9.